Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06964009 · ClinicalTrials.gov registry record · Phase 1
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
A Phase 1 study of Ovarian Cancer and Ovarian Carcinoma, sponsored by Elizabeth Stover, MD, PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT06964009: Recruiting Phase 1 study of Ovarian Cancer and Ovarian Carcinoma, sponsored by Elizabeth Stover, MD, PhD.
NCT06964009 is a Phase 1 study of Ovarian Cancer and Ovarian Carcinoma that is actively recruiting participants, run by Elizabeth Stover, MD, PhD. The registered enrollment target is 30 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06964009, a Phase 1 study of Ovarian Cancer and Ovarian Carcinoma, is actively recruiting participants, sponsored by Elizabeth Stover, MD, PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein) * Paclitaxel (a type of antimicrotubule agent)
Primary Outcome
The DT2216 MTD in combination with paclitaxel is determined by the number of participants who experience dose-limiting toxicity (DLT) during cycle 1 and up to start of cycle 2. Dose (de-)escalation rules and the related selection of the MTD are based on the Bayesian Optimal Interval Design (BOIN).
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG DT2216
Study Locations (3)
Massachusetts
- Beth Israel Deaconess Medical Center (BIDMC) - Boston
- Dana Farber Cancer Institute - Boston
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 1 |
What NCT06964009 shows while recruiting
NCT06964009 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower).
The record links to 4 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT06964009 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06964009 about?
NCT06964009 is a clinical study titled "DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer". The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting c...
What is the current status of trial NCT06964009?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-09-22. Estimated completion is 2027-12-30.
What conditions does trial NCT06964009 study?
This clinical trial studies the following conditions: Ovarian Cancer, Ovarian Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Ovary Cancer.
What interventions are being tested in trial NCT06964009?
The interventions under investigation include: Paclitaxel (DRUG), DT2216 (DRUG).
Who is sponsoring clinical trial NCT06964009?
This trial is sponsored by Elizabeth Stover, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06964009 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06964009's enrollment target sits among peer trials
30 252nd of 322 higher than 62 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI